Xiaflex and Neutrophil percentage decreased - a phase IV clinical study of FDA data


We study 4,984 people who take Xiaflex or have Neutrophil percentage decreased. No report of Neutrophil percentage decreased is found in people who take Xiaflex.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 28, 2022

No report is found.

What is Xiaflex?

Xiaflex has active ingredients of collagenase clostridium histolyticum. eHealthMe is studying from 4,357 Xiaflex users for its effectiveness, alternative drugs and more.

What is Neutrophil Percentage Decreased?

Neutrophil percentage decreased is found to be associated with 467 drugs and 233 conditions by eHealthMe.

Do you take Xiaflex and have Neutrophil percentage decreased?

Check whether Neutrophil percentage decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Neutrophil percentage decreased and when was it recovered:

Expand to all the drugs that have ingredients of collagenase clostridium histolyticum:

Alternative drugs to, pros and cons of Xiaflex:

Neutrophil percentage decreased treatments and more:

COVID vaccines that are related to Neutrophil percentage decreased:

All the drugs that are associated with Neutrophil percentage decreased:

All the conditions that are associated with Neutrophil percentage decreased:

How the study uses the data?

The study uses data from the FDA. It is based on collagenase clostridium histolyticum (the active ingredients of Xiaflex) and Xiaflex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: